REG - Oncimmune Hldgs PLC - ImmunoINSIGHTS contract signed with global pharma

Oncimmune HoldingsAnnouncement

04/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220304:nRSD5836Da&default-theme=true

RNS Number : 5836D  Oncimmune Holdings PLC  04 March 2022

4 March 2022

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

ImmunoINSIGHTS contract signed with leading top 10 global pharmaceutical
company to profile biomarkers in CIDP

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces the signing of a commercial contract with a new top 10
global pharmaceutical company by revenue, initially focusing on the
autoantibody profiling of Chronic Inflammatory Demyelinating
Polyradiculoneuropathy ("CIDP").

 

Under the terms of this new contract, Oncimmune will utilise its specific
high-throughput proprietary biomarker discovery platform, SeroTag(TM), to
identify autoantibodies related to CIDP. Specifically, ImmunoINSIGHTS will
produce and validate CIDP specific antigens utilising the SeroTag(TM) platform
to screen clinical samples from CIDP patients for related autoantibodies.

 

CIDP is a rare type of autoimmune disease which attacks the myelin sheaths,
the fatty coverings intended to insulate and protect nerves. Often referred to
as Guillain-Barré syndrome (GBS) in its acute phase, CIDP is chronic,
difficult to diagnose and can lead to permanent physical impairment if not
treated in its earliest stages.

 

Dr Adam M Hill, CEO of Oncimmune said: "We are pleased to announce this
contract with another leading pharmaceutical company, adding to the growing
list of global partners, working with us in the rare disease space where there
is a real clinical need and opportunity to make a significant impact. This
contract will make full use of the unique attributes of our SeroTag(TM)
platform, and the competencies amongst our scientific colleagues, who are
world leaders in autoimmune profiling.

 

"As is typical with SeroTag(TM) contracts, there is potential for the initial
discovery work in autoantibodies to progress to further research and support
for therapeutic development, creating and refining CIPD-specific NavigAID(TM)
panels using additional data and markers to guide drug development and inform
patient and disease stratification."

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organisations to optimise drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com

 

What is SeroTag(TM)?

 

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our
ImmunoINSIGHTS services to discover and validate novel biomarkers can help
stratify patients in multiple cancer indications and with different autoimmune
diseases.

 

This high-throughput, multiplex technology is based on one of the largest,
in-house protein libraries, as well as a unique, ever-growing repository of
disease data for indications including, but not limited to, autoimmune
diseases and cancer. As a result, SeroTag(TM) is helping to address and
monitor a number of challenges currently hindering the successful development
and broader application of both cancer immunotherapies and treatments for
autoimmune diseases.

 

The platform is being applied to discover and validate biomarkers and develop
precision diagnostic tools from minimally invasive liquid biopsies.
SeroTag(TM) analyses autoantibodies-some of the most stable analytes-and is
used most frequently for the identification of IgG isoforms, in addition to
IgM and IgA, from just a few drops of serum.

 

The SeroTag platform acts as the primary discovery engine that feeds into the
creation of Oncimmune's NavigAID(TM) disease-specific stratification panels.
These precision medicine tools which are enabling patient and disease
stratification and support therapeutic development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPURUWUPPGQW